Delivery Order SPE2DB25D3504-SPE2DB26FVTKE
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Febuxostat 80 mg tablets (30-count supply) valued at $1,799.27. This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by September 3, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this pharmaceutical delivery through its Corporate Office division. This award represents a single delivery order under...
- The Defense Logistics Agency awarded a delivery order valued at $1,382.30 to AmerisourceBergen Drug Corp for the supply of Febuxostat 40 mg tablets (30-count units) on October 30, 2025, with completion targeted for October 31, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The order represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $2,323.73 to AmerisourceBergen Drug Corp for the supply of Febuxostat 40 mg tablets (30-count) on September 17, 2025, with completion scheduled for September 18, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a delivery order under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with the DLA. The product will be delivered to the company's corporate office...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,273.53 on July 28, 2025, for the supply of Febuxostat 80 mg tablets (30-count units). This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of July 29, 2025. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $1,629.42 to AmerisourceBergen Drug Corp for the supply of Febuxostat 40 mg tablets (30-count packages). This firm fixed-price, non-set-aside delivery order was executed on August 18, 2025, with an ultimate completion date of August 19, 2025. The product will be performed and delivered from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract action under...
- The Defense Logistics Agency awarded a $4,789.17 delivery order to AmerisourceBergen Drug Corp on October 28, 2025, for the supply of Febuxostat 40 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price delivery order is set to be completed by October 29, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order valued at $4,747.98 to AmerisourceBergen Drug Corp for the supply of Febuxostat 40 mg tablets in quantities of 30, with an ultimate completion date of August 11, 2025. This contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,353.14 to AmerisourceBergen Drug Corp for the supply of Febuxostat 40 mg tablets (30-count units) on May 27, 2025, with an ultimate completion date of May 28, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a child delivery order under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 26, 2025, for the supply of Febuxostat 80 mg tablets (30-count units) under a firm fixed-price contract with a ceiling value of $6,529.09. This non-set-aside award was competitively procured and is set for completion by June 27, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This...
- The Defense Logistics Agency awarded a $7,885.53 delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Febuxostat 40 mg tablets (30-count units). This is a firm fixed price, non-set-aside contract with a completion deadline of September 25, 2025, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- SPE2DB25D3504Indefinite Delivery Contract
- SPE2DB25D3504-SPE2DB26FVTKEDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,002.66 to AmerisourceBergen Drug Corp for the supply of Febuxostat 80 mg tablets (30-count) on November 3, 2025, with completion expected by November 4, 2025. This firm fixed price contract represents a non-set-aside, competitively awarded delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order exemplifies AmerisourceBergen's role as a critical pharmaceutical distributor for federal military healthcare systems. As a major prime vendor under the DLA's comprehensive pharmaceutical procurement framework, AmerisourceBergen supplies a broad portfolio of medications and medical supplies to support Defense Health Agency operations and other federal healthcare customers. The award of this relatively small transaction for Febuxostat, a medication used to treat gout and hyperuricemia, reflects the routine fulfillment of clinical pharmaceutical needs across military healthcare networks through the established indefinite delivery contract vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.0k | 11/3/25 |